Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib
Overview
Authors
Affiliations
Diffuse intrinsic pontine glioma (DIPG) is an invariably fatal brain tumor occurring predominantly in children. Up to 90% of pediatric DIPGs harbor a somatic heterozygous mutation resulting in the replacement of lysine 27 with methionine (K27M) in genes encoding histone H3.3 (H3F3A, 65%) or H3.1 (HIST1H3B, 25%). Several studies have also identified recurrent truncating mutations in the gene encoding protein phosphatase 1D, , in 9%-23% of DIPGs. Here, we sought to investigate the therapeutic potential of targeting PPM1D, alone or in combination with inhibitors targeting specific components of DNA damage response pathways in patient-derived DIPG cell lines. We found that GSK2830371, an allosteric PPM1D inhibitor, suppressed the proliferation of -mutant, but not wild-type DIPG cells. We further observed that PPM1D inhibition sensitized -mutant DIPG cells to PARP inhibitor (PARPi) treatment. Mechanistically, combined PPM1D and PARP inhibition show synergistic effects on suppressing a p53-dependent RAD51 expression and the formation of RAD51 nuclear foci, possibly leading to impaired homologous recombination (HR)-mediated DNA repair in -mutant DIPG cells. Collectively, our findings reveal the potential role of the PPM1D-p53 signaling axis in the regulation of HR-mediated DNA repair and provide preclinical evidence demonstrating that combined inhibition of PPM1D and PARP1/2 may be a promising therapeutic combination for targeting -mutant DIPG tumors. IMPLICATIONS: The findings support the use of PARPi in combination with PPM1D inhibition against -mutant DIPGs.
The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.
Furst L, Roussel E, Leung R, George A, Best S, Whittle J Biology (Basel). 2024; 13(6).
PMID: 38927304 PMC: 11200883. DOI: 10.3390/biology13060424.
Radiotherapy and radio-sensitization in H3 -mutated diffuse midline gliomas.
Liu C, Kuang S, Wu L, Cheng Q, Gong X, Wu J CNS Neurosci Ther. 2023; 29(7):1721-1737.
PMID: 37157237 PMC: 10324372. DOI: 10.1111/cns.14225.
Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A, Galban S Neoplasia. 2023; 40:100899.
PMID: 37030112 PMC: 10119952. DOI: 10.1016/j.neo.2023.100899.
Liu G, Feng Y, Li J, Deng T, Yin A, Yan L EClinicalMedicine. 2022; 54:101767.
PMID: 36583171 PMC: 9793276. DOI: 10.1016/j.eclinm.2022.101767.
Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P, Markouli M, Strepkos D, Piperi C Curr Neuropharmacol. 2022; 21(7):1519-1535.
PMID: 36154607 PMC: 10472812. DOI: 10.2174/1570159X20666220922150456.